Research & Literature

Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal.

Pelosi G, Barbareschi M, Cavazza A, et al.

Lung cancer (Amsterdam, Netherlands) 2015; (87(3)):226-31.

Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach.

Salgia R

Future oncology (London, England) 2015; (11(3)):489-500 doi:10.2217/fon.14.275.

Long-term quality of life in early-stage non-small cell lung cancer patients treated with robotic stereotactic ablative radiation therapy.

Mathieu D, Campeau MP, Bahig H, et al.

Practical radiation oncology 2015; (5(4)):e365-73.

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

Oser MG, Niederst MJ, Sequist LV, Engelman JA

The Lancet. Oncology 2015; (16(4)):e165-72.

Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.

Uchida J, Kato K, Kukita Y, et al.

Clinical chemistry 2015; (61(9)):1191-6 doi:10.1373/clinchem.2015.241414.

Variations in cancer centers' use of cytology for the diagnosis of small cell lung carcinoma in the National Cancer Data Base.

Gansler T, Fedewa SA, Lin CC, et al.

Cancer cytopathology 2016; (124(1)):44-52 doi:10.1002/cncy.21610.

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.

Rudin CM, Ismaila N, Hann CL, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; (33(34)):4106-11 doi:10.1200/JCO.2015.63.7918.

Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis.

Palma DA, Warner A, Louie AV, et al.

Clinical lung cancer 2016; (17(4)):239-44.

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group.

Dietel M, Bubendorf L, Dingemans AM, et al.

Thorax 2016; (71(2)):177-84 doi:10.1136/thoraxjnl-2014-206677.

Epidemiology of Lung Cancer.

Schwartz AG, Cote ML

Advances in experimental medicine and biology 2016; (893()):21-41 doi:10.1007/978-3-319-24223-1_2.

Pairing smoking-cessation services with lung cancer screening: A clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco.

Fucito LM, Czabafy S, Hendricks PS, et al.

Cancer 2016; (122(8)):1150-9 doi:10.1002/cncr.29926.

Small cell lung cancer (SCLC): no treatment advances in recent years.

Koinis F, Kotsakis A, Georgoulias V

Translational lung cancer research 2016; (5(1)):39-50 doi:10.3978/j.issn.2218-6751.2016.01.03.

Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer.

Villar Álvarez F, Muguruza Trueba I, Belda Sanchis J, et al.

Archivos de bronconeumologia 2016; (52(7)):378-88.

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.

Thompson JC, Yee SS, Troxel AB, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2016; (22(23)):5772-5782 doi:10.1158/1078-0432.CCR-16-1231.

Peri- and postoperative management of stage I-III Non Small Cell Lung Cancer: Which quality of care indicators are evidence-based?

Numan RC, Berge MT, Burgers JA, et al.

Lung cancer (Amsterdam, Netherlands) 2016; (101()):129-136 doi:10.1016/j.lungcan.2016.06.007.

Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Rami-Porta R, Asamura H, Travis WD, Rusch VW

CA: a cancer journal for clinicians 2017; (67(2)):138-155 doi:10.3322/caac.21390.

Biological therapies in nonsmall cell lung cancer.

Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F, Paz-Ares L

The European respiratory journal 2017; (49(3)) doi:10.1183/13993003.01520-2016.

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

Faivre-Finn C, Snee M, Ashcroft L, et al.

The Lancet. Oncology 2017; (18(8)):1116-1125 doi:10.1016/S1470-2045(17)30318-2.

What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist.

Ghanem S, El Bitar S, Hossri S, et al.

Cancer management and research 2017; (9()):267-278 doi:10.2147/CMAR.S139253.

Cognitive functioning in long-term cancer survivorship: A survey utilizing both standardized neuropsychological and self-report measures.

Muzzatti B, Giovannini L, Flaiban C, et al.

Applied neuropsychology. Adult 2019; (26(2)):173-180 doi:10.1080/23279095.2017.1387551.

Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline.

Schneider BJ, Daly ME, Kennedy EB, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; (36(7)):710-719 doi:10.1200/JCO.2017.74.9671.

Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.

Osmani L, Askin F, Gabrielson E, Li QK

Seminars in cancer biology 2018; (52(Pt 1)):103-109 doi:10.1016/j.semcancer.2017.11.019.

Bronchial Artery Embolization for the Treatment of Acute Hemoptysis.

Cody O'Dell M, Gill AE, Hawkins CM

Techniques in vascular and interventional radiology 2017; (20(4)):263-265 doi:10.1053/j.tvir.2017.10.006.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, et al.

Archives of pathology & laboratory medicine 2018; (142(3)):321-346 doi:10.5858/arpa.2017-0388-CP.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018; (13(3)):323-358 doi:10.1016/j.jtho.2017.12.001.

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

Lindeman NI, Cagle PT, Aisner DL, et al.

The Journal of molecular diagnostics : JMD 2018; (20(2)):129-159 doi:10.1016/j.jmoldx.2017.11.004.

Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer.

Shroff GS, de Groot PM, Papadimitrakopoulou VA, et al.

Radiologic clinics of North America 2018; (56(3)):485-495 doi:10.1016/j.rcl.2018.01.012.

Imaging of urgencies and emergencies in the lung cancer patient.

De Potter B, Huyskens J, Hiddinga B, et al.

Insights into imaging 2018; (9(4)):463-476 doi:10.1007/s13244-018-0605-6.

A Systematic Review and Narrative Synthesis to Explore the Effectiveness of Exercise-Based Interventions in Improving Fatigue, Dyspnea, and Depression in Lung Cancer Survivors.

Henshall CL, Allin L, Aveyard H

Cancer nursing 2019; (42(4)):295-306 doi:10.1097/NCC.0000000000000605.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Brahmer JR, Govindan R, Anders RA, et al.

Journal for immunotherapy of cancer 2018; (6(1)):75 doi:10.1186/s40425-018-0382-2.

Rapid Fire: Superior Vena Cava Syndrome.

Zimmerman S, Davis M

Emergency medicine clinics of North America 2018; (36(3)):577-584 doi:10.1016/j.emc.2018.04.011.

Shared decision-making conversations and smoking cessation interventions: critical components of low-dose CT lung cancer screening programs.

Lowenstein LM, Deyter GMR, Nishi S, et al.

Translational lung cancer research 2018; (7(3)):254-271 doi:10.21037/tlcr.2018.05.10.

Comparison of 7th and 8th editions of the UICC/AJCC TNM staging for non-small cell lung cancer in a non-metastatic North American cohort undergoing primary radiation treatment.

Koul R, Rathod S, Dubey A, et al.

Lung cancer (Amsterdam, Netherlands) 2018; (123()):116-120 doi:10.1016/j.lungcan.2018.06.029.

Oncologic Emergencies: Recognition and Initial Management.

Higdon ML, Atkinson CJ, Lawrence KV

American family physician 2018; (97(11)):741-748.

The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.

Evans M, O'Sullivan B, Hughes F, et al.

Pathology oncology research : POR 2020; (26(1)):79-89 doi:10.1007/s12253-018-0469-6.

Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma.

Miller TE, Yang M, Bajor D, et al.

Journal of clinical pathology 2018; (71(12)):1108-1115 doi:10.1136/jclinpath-2018-205396.

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

Horn L, Mansfield AS, Szczęsna A, et al.

The New England journal of medicine 2018; (379(23)):2220-2229 doi:10.1056/NEJMoa1809064.

[Predictive value of PD-L1 diagnostics].

Schildhaus HU

Der Pathologe 2018; (39(6)):498-519 doi:10.1007/s00292-018-0507-x.

Stereotactic body radiation therapy for non-small cell lung cancer: A review.

Prezzano KM, Ma SJ, Hermann GM, et al.

World journal of clinical oncology 2019; (10(1)):14-27 doi:10.5306/wjco.v10.i1.14.

Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study.

Mendoza TR, Kehl KL, Bamidele O, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2019; (27(9)):3439-3447 doi:10.1007/s00520-018-4632-0.

Using a Dedicated Interventional Pulmonology Practice Decreases Wait Time Before Treatment Initiation for New Lung Cancer Diagnoses.

Benn BS, Parikh M, Tsau PH, et al.

Lung 2019; (197(2)):249-255 doi:10.1007/s00408-019-00207-6.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazieres J, Drilon A, Lusque A, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2019; (30(8)):1321-1328 doi:10.1093/annonc/mdz167.

What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China.

Xing PY, Zhu YX, Wang L, et al.

Cancer medicine 2019; (8(8)):4055-4069 doi:10.1002/cam4.2256.

The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations.

Feng SH, Yang ST

Diagnostic and interventional radiology (Ankara, Turkey) 2019; (25(4)):270-279 doi:10.5152/dir.2019.18458.

Fear of cancer recurrence across the survivorship trajectory: Results from a survey of adult long-term cancer survivors.

Götze H, Taubenheim S, Dietz A, et al.

Psycho-oncology 2019; (28(10)):2033-2041 doi:10.1002/pon.5188.

Current Diagnosis and Management of Small-Cell Lung Cancer.

Wang S, Zimmermann S, Parikh K, et al.

Mayo Clinic proceedings 2019; (94(8)):1599-1622 doi:10.1016/j.mayocp.2019.01.034.

Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.

Harrison PT, Vyse S, Huang PH

Seminars in cancer biology 2020; (61()):167-179 doi:10.1016/j.semcancer.2019.09.015.

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

Paz-Ares L, Dvorkin M, Chen Y, et al.

Lancet (London, England) 2019; (394(10212)):1929-1939 doi:10.1016/S0140-6736(19)32222-6.

Changing equipoise in the landscape of radiation for oligometastatic lung cancer.

Schroeder SR, Leenders M, Iyengar P, de Ruysscher D

Translational lung cancer research 2019; (8(Suppl 2)):S184-S191 doi:10.21037/tlcr.2019.07.09.

Screening for fear of cancer recurrence: Instrument validation and current status in early stage lung cancer patients.

Lee YH, Hu CC, Humphris G, et al.

Journal of the Formosan Medical Association = Taiwan yi zhi 2020; (119(6)):1101-1108 doi:10.1016/j.jfma.2019.10.007.

Radiation Oncology Emergencies.

Narang M, Mohindra P, Mishra M, et al.

Hematology/oncology clinics of North America 2020; (34(1)):279-292 doi:10.1016/j.hoc.2019.09.004.

Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.

Schneider BJ, Ismaila N, Aerts J, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(7)):753-766 doi:10.1200/JCO.19.02748.

Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline.

Simone CB, Bogart JA, Cabrera AR, et al.

Practical radiation oncology 2020; (10(3)):158-173 doi:10.1016/j.prro.2020.02.009.

Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma.

Raman L, Van der Linden M, Van der Eecken K, et al.

Genome medicine 2020; (12(1)):35 doi:10.1186/s13073-020-00735-4.

Advances in the Treatment of Stage III Non-Small Cell Lung Cancer.

Myall NJ, Das M

Clinics in chest medicine 2020; (41(2)):211-222 doi:10.1016/j.ccm.2020.02.008.

Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record.

Pagni F, Malapelle U, Doglioni C, et al.

Cancers 2020; (12(7)) doi:10.3390/cancers12071800.

Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.

Saxena P, Singh PK, Malik PS, Singh N

Current treatment options in oncology 2020; (21(8)):69 doi:10.1007/s11864-020-00768-2.

Molecular Pathology of Primary Non-small Cell Lung Cancer.

Suster DI, Mino-Kenudson M

Archives of medical research 2020; (51(8)):784-798 doi:10.1016/j.arcmed.2020.08.004.

Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Pritchett MA, Camidge DR, Patel M, et al.

JCO precision oncology 2019; (3()) doi:10.1200/PO.18.00299.

First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.

Satouchi M, Nosaki K, Takahashi T, et al.

Cancer science 2020; (111(12)):4480-4489 doi:10.1111/cas.14647.

A review on the impact of lung cancer multidisciplinary care on patient outcomes.

Heinke MY, Vinod SK

Translational lung cancer research 2020; (9(4)):1639-1653 doi:10.21037/tlcr.2019.11.03.

Diagnostic Accuracy of Next Generation Sequencing Panel using Circulating Tumor DNA in Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Sebastião MM, Ho RS, de Carvalho JPV, Nussbaum M

Journal of health economics and outcomes research 2020; (7(2)):158-163 doi:10.36469/jheor.2020.17088.

Superior vena cava syndrome.

Klein-Weigel PF, Elitok S, Ruttloff A, et al.

VASA. Zeitschrift fur Gefasskrankheiten 2020; (49(6)):437-448 doi:10.1024/0301-1526/a000908.

Lung cancer symptoms at diagnosis: results of a nationwide registry study.

Ruano-Raviña A, Provencio M, Calvo de Juan V, et al.

ESMO open 2020; (5(6)):e001021 doi:10.1136/esmoopen-2020-001021.

What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?

Ricciuti B, Awad MM

Cancer journal (Sudbury, Mass.) 2020; (26(6)):485-495 doi:10.1097/PPO.0000000000000489.

'Care for Outcomes': systematic development of a set of outcome indicators to improve patient-relevant outcomes for patients with lung cancer.

Cramer-van der Welle CM, van Loenhout L, van den Borne BE, et al.

BMJ open 2021; (11(1)):e043229 doi:10.1136/bmjopen-2020-043229.

Pathology and Classification of SCLC.

Raso MG, Bota-Rabassedas N, Wistuba II

Cancers 2021; (13(4)) doi:10.3390/cancers13040820.

Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement.

, Krist AH, Davidson KW, et al.

JAMA 2021; (325(10)):962-970 doi:10.1001/jama.2021.1117.

FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.

Mathieu L, Shah S, Pai-Scherf L, et al.

The oncologist 2021; (26(5)):433-438 doi:10.1002/onco.13752.

Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.

Chaft JE, Rimner A, Weder W, et al.

Nature reviews. Clinical oncology 2021; (18(9)):547-557 doi:10.1038/s41571-021-00501-4.

Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists.

Glatzer M, Leskow P, Caparrotti F, et al.

Translational lung cancer research 2021; (10(4)):1960-1968 doi:10.21037/tlcr-20-1210.

Stage I non-small cell lung cancer: Treatment modalities, Dutch daily practice and future perspectives.

Hopstaken JS, de Ruiter JC, Damhuis RAM, et al.

Cancer treatment and research communications 2021; (28()):100404 doi:10.1016/j.ctarc.2021.100404.

Post-traumatic stress symptoms in long-term disease-free cancer survivors and their family caregivers.

De Padova S, Grassi L, Vagheggini A, et al.

Cancer medicine 2021; (10(12)):3974-3985 doi:10.1002/cam4.3961.

Delivery of Financial Navigation Services Within National Cancer Institute-Designated Cancer Centers.

de Moor JS, Mollica M, Sampson A, et al.

JNCI cancer spectrum 2021; (5(3)) doi:10.1093/jncics/pkab033.

Trends in Patient Volume by Hospital Type and the Association of These Trends With Time to Cancer Treatment Initiation.

Frosch ZAK, Illenberger N, Mitra N, et al.

JAMA network open 2021; (4(7)):e2115675 doi:10.1001/jamanetworkopen.2021.15675.

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.

Guaitoli G, Tiseo M, Di Maio M, et al.

Translational lung cancer research 2021; (10(6)):2890-2916 doi:10.21037/tlcr-20-941.

The emergency department evaluation and management of massive hemoptysis.

Atchinson PRA, Hatton CJ, Roginski MA, et al.

The American journal of emergency medicine 2021; (50()):148-155 doi:10.1016/j.ajem.2021.07.041.

American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer.

Amini A, Verma V, Simone CB, et al.

International journal of radiation oncology, biology, physics 2022; (112(2)):361-375 doi:10.1016/j.ijrobp.2021.09.022.

Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.

Aggarwal C, Bubendorf L, Cooper WA, et al.

Lung cancer (Amsterdam, Netherlands) 2021; (162()):42-53 doi:10.1016/j.lungcan.2021.09.003.

Evaluation of local aggressive lung therapy versus systemic therapy in oligometastatic non-small cell lung cancer: a systematic review and meta-analysis.

Zhang C, Ma N, Zhang Q, et al.

Journal of thoracic disease 2021; (13(10)):5899-5910 doi:10.21037/jtd-21-957.

Implementation and Effectiveness of a Veterans Affairs-Based Comprehensive Lung Cancer Survivorship Program.

Rabe BJ, Stafford JW, Hassinger AD, et al.

Journal of cardiopulmonary rehabilitation and prevention 2022; (42(3)):196-201 doi:10.1097/HCR.0000000000000658.

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Ganti AKP, Loo BW, Bassetti M, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(12)):1441-1464.

A National Survey of Palliative Care Team Compositions.

Chen J, de la Rosa A, Lai D, et al.

Journal of palliative care 2022; (37(2)):142-151 doi:10.1177/08258597211058963.

Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.

Bogart JA, Waqar SN, Mix MD

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(6)):661-670 doi:10.1200/JCO.21.01639.

Patients' Perceptions at Diagnosis: Lung Cancer Discovery and Provider Relationships.

Somayaji D, Mohedat H, Dean GE, Dickerson SS

Cancer nursing 2022; (45(5)):397-405 doi:10.1097/NCC.0000000000001050.

Improving coordination of lung cancer care at a tertiary healthcare center in Saudi Arabia.

Alkhathlan A, Alfaiz R, Almusallam G, et al.

Saudi medical journal 2022; (43(3)):313-316 doi:10.15537/smj.2022.43.3.20210750.

Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system.

Perdrizet K, Stockley TL, Law JH, et al.

Cancer treatment and research communications 2022; (31()):100534 doi:10.1016/j.ctarc.2022.100534.

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

Forde PM, Spicer J, Lu S, et al.

The New England journal of medicine 2022; (386(21)):1973-1985 doi:10.1056/NEJMoa2202170.

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.

Herbst RS, Majem M, Barlesi F, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(29)):3383-3393 doi:10.1200/JCO.22.00227.

Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Ettinger DS, Wood DE, Aisner DL, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(5)):497-530.

Lung Cancer: Diagnosis, Treatment Principles, and Screening.

Kim J, Lee H, Huang BW

American family physician 2022; (105(5)):487-494.

Evaluation and Treatment of Massive Hemoptysis.

Prey B, Francis A, Williams J, Krishnadasan B

The Surgical clinics of North America 2022; (102(3)):465-481 doi:10.1016/j.suc.2021.11.002.

The effect of psychological interventions on fear of cancer recurrence in breast cancer survivors: A systematic review and meta-analysis.

Lyu MM, Siah RC, Lam ASL, Cheng KKF

Journal of advanced nursing 2022; (78(10)):3069-3082 doi:10.1111/jan.15321.

Stigma in Early-Stage Lung Cancer.

Bédard S, Sasewich H, Culling J, et al.

Annals of behavioral medicine : a publication of the Society of Behavioral Medicine 2022; (56(12)):1272-1283 doi:10.1093/abm/kaac021.

Cancer Fear, Emotion Regulation, and Emotional Distress in Patients With Newly Diagnosed Lung Cancer.

Su CH, Liu Y, Hsu HT, Kao CC

Cancer nursing 2024; (47(1)):56-63 doi:10.1097/NCC.0000000000001150.

Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors.

Nakagawa N, Kawakami M

Frontiers in oncology 2022; (12()):952393 doi:10.3389/fonc.2022.952393.

Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.

Lai GGY, Guo R, Drilon A, Shao Weng Tan D

Cancer treatment reviews 2022; (110()):102444 doi:10.1016/j.ctrv.2022.102444.

Lung Cancer Screening.

Choi HK, Mazzone PJ

The Medical clinics of North America 2022; (106(6)):1041-1053 doi:10.1016/j.mcna.2022.07.007.

European Respiratory Society guideline on various aspects of quality in lung cancer care.

Blum TG, Morgan RL, Durieux V, et al.

The European respiratory journal 2023; (61(2)) doi:10.1183/13993003.03201-2021.

Interventions for superior vena cava syndrome.

Sen I, Kalra M, Gloviczki P

The Journal of cardiovascular surgery 2022; (63(6)):674-681 doi:10.23736/S0021-9509.22.12448-1.

Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations.

Sun A, Abdulkarim B, Blais N, et al.

Lung cancer (Amsterdam, Netherlands) 2023; (179()):107166 doi:10.1016/j.lungcan.2023.03.002.

Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine.

Villaruz LC, Socinski MA, Weiss J

Frontiers in oncology 2023; (13()):1124167 doi:10.3389/fonc.2023.1124167.

ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III Non-Small Cell Lung Cancer.

Simone CB, Bradley J, Chen AB, et al.

Practical radiation oncology 2023; (13(3)):195-202 doi:10.1016/j.prro.2023.01.005.

Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.

Iyengar P, All S, Berry MF, et al.

Practical radiation oncology 2023; (13(5)):393-412 doi:10.1016/j.prro.2023.04.004.

Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial.

García-Pardo M, Czarnecka-Kujawa K, Law JH, et al.

JAMA network open 2023; (6(7)):e2325332 doi:10.1001/jamanetworkopen.2023.25332.

Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia.

Mahrous M, Omar Jebriel A, Allehebi A, et al.

Cureus 2023; (15(7)):e41992 doi:10.7759/cureus.41992.

[Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer - Interdisciplinary Guideline of the German Respiratory Society and the German Cancer Society - Abridged Version].

Schütte W, Gütz S, Nehls W, et al.

Pneumologie (Stuttgart, Germany) 2023; (77(10)):671-813 doi:10.1055/a-2029-0134.

Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).

Nakamichi S, Kubota K, Misumi T, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(6)):1104-1110 doi:10.1158/1078-0432.CCR-23-2568.

Sublobar Resection vs Lobectomy for Stage IA Non-Small Cell Lung Carcinoma-Takeaways From Modern Randomized Trials.

Kneuertz PJ, Ferrari-Light D, Altorki NK

The Annals of thoracic surgery 2024; (117(5)):897-903 doi:10.1016/j.athoracsur.2023.12.008.

Design of HL7 FHIR Profiles for Pathology Reports Integrated with Pathology Images.

Lien CY, Ting TY, Kuo LC, et al.

Studies in health technology and informatics 2024; (310()):13-17 doi:10.3233/SHTI230918.

Association between surgical quality and long-term survival in lung cancer.

Lee JD, Zheng R, Okusanya OT, et al.

Lung cancer (Amsterdam, Netherlands) 2024; (190()):107511 doi:10.1016/j.lungcan.2024.107511.

Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology.

Laguna JC, García-Pardo M, Alessi J, et al.

Therapeutic advances in medical oncology 2024; (16()):17588359241231260 doi:10.1177/17588359241231260.

Rational and design of prophylactic cranial irradiation (PCI) and brain MRI surveillance versus brain MRI surveillance alone in patients with limited-stage small cell lung cancer achieving complete remission (CR) of tumor after chemoradiotherapy: a multicenter prospective randomized study.

Chen M, Li R, Kong Y, et al.

BMC cancer 2024; (24(1)):429 doi:10.1186/s12885-024-12123-x.

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.

Wu YL, Dziadziuszko R, Ahn JS, et al.

The New England journal of medicine 2024; (390(14)):1265-1276 doi:10.1056/NEJMoa2310532.

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.

Sholl LM, Awad M, Basu Roy U, et al.

Archives of pathology & laboratory medicine 2024; (148(7)):757-774 doi:10.5858/arpa.2023-0536-CP.

Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up.

Gadgeel SM, Rodríguez-Abreu D, Halmos B, et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2024; (19(8)):1228-1241 doi:10.1016/j.jtho.2024.04.011.

Perioperative Nivolumab in Resectable Lung Cancer.

Cascone T, Awad MM, Spicer JD, et al.

The New England journal of medicine 2024; (390(19)):1756-1769 doi:10.1056/NEJMoa2311926.

Survivorship in Advanced Lung Cancer: Understanding a New Landscape and Opportunities.

Presley CJ, Dalal N, Davenport AP, et al.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2024; (44(3)):e433298 doi:10.1200/EDBK_433298.

Lung cancer in the emergency department.

Walder JR, Faiz SA, Sandoval M

Emergency cancer care 2023; (2(1)):3 doi:10.1186/s44201-023-00018-9.

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.

Filippi AR, Bar J, Chouaid C, et al.

ESMO open 2024; (9(6)):103464 doi:10.1016/j.esmoop.2024.103464.

Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer.

Spicer JD, Cascone T, Wynes MW, et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2024; (19(10)):1373-1414 doi:10.1016/j.jtho.2024.06.010.

Molecular testing in non-small cell lung cancer: A consensus recommendation.

Lai GGY, Cheng XM, Ang YL, et al.

Annals of the Academy of Medicine, Singapore 2023; (52(7)):364-373 doi:10.47102/annals-acadmedsg.2022473.

Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer.

Li T, Ma W, Al-Obeidi E

Cancers 2024; (16(13)) doi:10.3390/cancers16132350.

Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis.

Huang S, Huang Z, Huang X, et al.

Frontiers in immunology 2024; (15()):1375136 doi:10.3389/fimmu.2024.1375136.

Biomarker Testing for Guiding Precision Medicine for Patients With Non-Small Cell Lung Cancer.

Fox AH, Alexander M, Forcucci JA, Silvestri GA

Chest 2024; (166(5)):1239-1249 doi:10.1016/j.chest.2024.08.006.

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.

Spicer JD, Garassino MC, Wakelee H, et al.

Lancet (London, England) 2024; (404(10459)):1240-1252 doi:10.1016/S0140-6736(24)01756-2.

TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer.

Okamoto I, Kuyama S, Girard N, et al.

Future oncology (London, England) 2024; (20(37)):2927-2936 doi:10.1080/14796694.2024.2409621.

ADRIATIC: When face value is enough.

Addeo A, Liu SV

Med (New York, N.Y.) 2024; (5(11)):1348-1350 doi:10.1016/j.medj.2024.10.004.

Association of whole grain food consumption with lung cancer risk: a prospective cohort study.

Wang K, Zhao J, Yang D, et al.

Cancer cell international 2025; (25(1)):14 doi:10.1186/s12935-025-03634-z.

Australia's National Lung Cancer Screening Program-It's Time to Address the Stigma in the Room.

Rose S, McFadden K, Harrison NJ, et al.

Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals 2025; (36(2)):e70011 doi:10.1002/hpja.70011.

Small Cell Lung Cancer: A Review.

Kim SY, Park HS, Chiang AC

JAMA 2025; (333(21)):1906-1917 doi:10.1001/jama.2025.0560.

Surveillance With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of Patients With Stage I-to-III Lung Cancer After Completion of Curative treatment (SUPE_R): A Randomized Controlled Trial.

Guldbrandsen KF, Bloch M, Skougaard K, et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2025; (20(8)):1086-1097 doi:10.1016/j.jtho.2025.04.003.

Efficacy of behavioral activation in reducing fear of cancer recurrence in non-small cell lung cancer patients: a randomized controlled trial.

Ge H, Li A, Huang R, et al.

American journal of cancer research 2025; (15(4)):1806-1819 doi:10.62347/ZSKM4538.

Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.

Occhipinti M, Imbimbo M, Ferrara R, et al.

The Cochrane database of systematic reviews 2025; (5()):CD015140 doi:10.1002/14651858.CD015140.pub2.

Dermatologic Adverse Event Mitigation and Management Strategies with Amivantamab + Lazertinib Therapy for Advanced Non-Small Cell Lung Cancer: A Vodcast.

Nguyen D, Santos ES

Targeted oncology 2025; (20(5)):737-742 doi:10.1007/s11523-025-01163-3.

Current Controversies and Challenges in Non-Oncogene-Addicted Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Review.

Jongbloed M, Bortolot M, Willmann J, et al.

JAMA oncology 2025; (11(11)):1385-1392 doi:10.1001/jamaoncol.2025.2891.

The American Cancer Society National Lung Cancer Roundtable strategic plan: Tobacco treatment in the context of lung cancer screening.

Fathi JT, Cinciripini PM, DePrimo MJ, et al.

Cancer 2025; (131(18)):e35972 doi:10.1002/cncr.35972.

Sublobar resection or lobectomy for stage Ia non-small cell lung cancer: a systematic review and meta-analysis.

Dixon LK, Barber E, Cook A, et al.

BMJ open respiratory research 2025; (12(1)) doi:10.1136/bmjresp-2025-003234.

Lung cancer biomarkers.

Mangang KN, Rao GSNK

Clinica chimica acta; international journal of clinical chemistry 2026; (580()):120707 doi:10.1016/j.cca.2025.120707.

The impact of cancer information overload on negative emotions in newly diagnosed lung cancer patients: the mediating role of fear of progression and the moderating role of social support.

Xu F, Zhang J, Li Q, et al.

Frontiers in psychiatry 2025; (16()):1676219 doi:10.3389/fpsyt.2025.1676219.

Expression of TRIM29 and its association with p40 and TTF1 in lung carcinoma.

Kumari N, Ahuja S, Rana S, et al.

Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia 2026; (59(1)):100849 doi:10.1016/j.patol.2025.100849.

Rare renal metastasis: Oligometastatic non-small cell lung cancer diagnosed with ultrasound guided renal biopsy.

Neerhut T, McMaster T, Homewood D, et al.

Radiology case reports 2026; (21(3)):1291-1296 doi:10.1016/j.radcr.2025.12.012.

Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.

Carnero-Gregorio M, Perera-Gordo E, de la Peña-Castro V, et al.

Genes 2026; (17(2)) doi:10.3390/genes17020209.

Durvalumab: A Review in Limited-Stage Small Cell Lung Cancer.

France NL, Syed YY

Targeted oncology 2026; (21(2)):299-307 doi:10.1007/s11523-026-01207-2.

Effects of a rehabilitation program based on home intelligent management platform guided among patient after lung cancer surgery: a randomized controlled trail.

Wang L, Liu C, Li H, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2026; (34(4)).

Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis.

Zhang B, Zhong R, Shi C, et al.

Nature communications 2026; (17(1)).

Lung Cancer Survivorship: Challenges and Care Needs.

Cani M, Cotogni P, Greco A, et al.

Cancers 2026; (18(17)) doi:10.3390/cancers18172856.